VO2 Max, powered by SleepFM.
A Stanford-licensed digital biomarker.
Our YC S26 track is VO2 Max on the SleepFM foundation model — validated in Nature Medicine (January 2026) across 585,000+ hours of PSG data and ~65,000 participants, with 130 predictable conditions at C-index ≥ 0.75. SLAM / nano-cream is long-horizon R&D, routed to EIC Pathfinder and NIH SBIR.
Founding team status is explicit: founder full-time; three technical leads part-time pending seed close; CTO offer outstanding. We state this plainly rather than imply otherwise.
VO₂ max is the control signal for cardiometabolic disease.
HbA1c, blood pressure, BNP, BMI each measure a single organ. VO₂ max measures the integrated output of the whole system — heart, lungs, blood, vessels, muscle metabolism — and equals or beats those risk factors at predicting death. It is the only such marker estimable passively and continuously from a wearable already on hundreds of millions of wrists. AeroGlyphics ↗ is our public-facing evidence + estimator surface for this thesis.
Estimator baseline: VO₂ ≈ 15 × (HRmax / HRrest) · Uth-Sørensen-Overgaard-Pedersen; HRmax = 208 − 0.7 × age · Tanaka, JACC 2001. Norms via FRIEND registry (Kaminsky, Mayo Clin Proc 2015). Not a clinical device — smartwatch VO₂ or CPET is a valid input.
Three tracks, one platform
YC narrative leads with VO2 Max + the Singapore enterprise pilot. SLAM is footnoted as long-horizon R&D.
VO2 Max — Stanford-licensed digital biomarker
Consumer + enterprise app built on the SleepFM foundation model (Nature Medicine, January 2026). Direct-to-consumer VO2 Max estimation from wrist wearables, with enterprise licensing to insurers and health systems.
Singapore health-system pilot
Phased 500-member pilot (months 1–6) with a Singapore health-system / insurer partner. Reference deal for the platform business model behind VO2 Max — English-language market, Smart Nation data infrastructure, and MOH-aligned digital health regulation.
SLAM / HealthOS (long-horizon R&D)
4-Layer Transformer + PEDOT:PSS nano-cream biosensor stack. Routed to EIC Pathfinder and NIH SBIR Phase I — not part of the YC S26 narrative.
Compliance & data residency — Singapore pilot operates under PDPA (2012, amended 2020), aligns with MOH HCSA digital-health licensing, and IMDA's Trusted Data Sharing Framework. All PHI stored in-region on SG-hosted infrastructure; de-identified training data governed by a DPA.
A digital definition of the biomarker — from wrist to plan to enterprise.
Life-science digital transformation, reforged for the wearable era. We bring a Bay Area foundation-model stack together with Boston clinical & regulatory rigor — MIT-trained engineering, Stanford-trained product, and an MD/PhD/MBA CMO. Not a consulting deck: a working platform your team can ship on.
Front-End Study (FES) engagements available for insurers, health systems, and pharma digital-health teams — translate a wearable signal into a covered benefit, a claim, or a Star Rating lever in 6–8 weeks.
Team — as it actually stands
Three-founder core with a clinician, product/MD candidate, and CTO. Advisors round out modeling, mobile, nano, and governance.
Founders
Advisors
Numbers
$27.5M Year-5 ARR is the VO2 Max + enterprise-licensing base case. The $42M SLAM-inclusive upside sits in the appendix, not the headline. Pre-seed $1.5M supersedes the earlier $2.5M blended figure (which included SBIR non-dilutive).
YC + SBIR Package — v3
Updated 13 July 2026 — Singapore-first reframing (PDPA/HCSA compliance note, Singapore partner shortlist appendix, regenerated Executive Summary + Business Plan + Pitch Deck, YC single-slide addendum). China / Ping An references removed throughout.
Compliance FAQ
PDPA · MOH HCSA · IMDA TDSF · HIPAA · GDPR — short answers; full detail in the Compliance FAQ doc.